Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Association of CYP2D6 metabolizer status with mammographic density change in response to tamoxifen treatment.

Breast cancer research : BCR - 1 Jan 2013

Li Jingmei, Czene Kamila, Brauch Hiltrud, Schroth Werner, Saladores Pilar, Li Yi, Humphreys Keith, Hall Per

Abstract excerpt

INTRODUCTION: Not all breast cancer patients respond to tamoxifen treatment, possibly due to genetic predisposition. As tamoxifen-induced reductions in percent mammographic density (PMD) have been linked to the risk and prognosis of breast cancer, we conducted a candidate gene study to investigate the association between germline CYP2D6 polymorphisms and PMD change. METHODS: Baseline and follow-up mammograms were...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents, Hormonal
Share to Breast Density

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Breast Neoplasms

Share to Cytochrome P-450 CYP2D6

Share to Mammary Glands, Human

Share to Prognosis

Share to Tamoxifen

Share to Treatment Outcome

Source

Open in PubMed Open full text

Identifiers

PMID: 24088226
DOI: 10.1186/bcr3495
PMCID: PMC3979120

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Association of CYP2D6 metabolizer status with mammographic density change in response to tamoxifen treatment.PMID 24088226Read ↗

CYP2D6 genotype predicts tamoxifen discontinuation and drug response: a secondary analysis of the KARISMA trial.Semantic proximity Read ↗

Clinical Relevance of CYP2D6 Genetics for Tamoxifen Response in Breast CancerSemantic proximity Read ↗

Impact of systemic adjuvant therapy and CYP2D6 activity on mammographic density in a cohort of tamoxifen-treated breast cancer patients.Semantic proximity Read ↗

CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the breast international group 1-98 trial.Semantic proximity Read ↗

CYP2D6 polymorphisms and the impact on tamoxifen therapy.Semantic proximity Read ↗

Tamoxifen Dose Escalation in CYP2D6 Poor Metabolizer Breast Cancer Patients and Associated Side EffectsSemantic proximity Read ↗

Relationships between CYP2D6 phenotype, breast cancer and hot flushes in women at high risk of breast cancer receiving prophylactic tamoxifen: results from the IBIS-I trial.Semantic proximity Read ↗

Association between CYP2D6 polymorphisms and outcomes among women with early stage breast cancer treated with tamoxifen.Semantic proximity Read ↗

CYP2D6 polymorphisms influence tamoxifen treatment outcomes in breast cancer patients: a meta-analysis.Semantic proximity Read ↗

CYP2D6*4 polymorphism: A new marker of response to hormonotherapy in male breast cancer?Semantic proximity Read ↗

CYP2D6 polymorphisms as predictors of outcome in breast cancer patients treated with tamoxifen: expanded polymorphism coverage improves risk stratification.Semantic proximity Read ↗

Association between genetic polymorphisms of CYP2D6 and outcomes in breast cancer patients with tamoxifen treatment.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.